Page 2 - Helsinn Advanced Synthesis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Helsinn advanced synthesis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Helsinn Advanced Synthesis Today - Breaking & Trending Today

Helsinn appoints Mary Lynne Hedley to Board of Directors

Helsinn appoints Mary Lynne Hedley to Board of Directors
April 29, 2021 03:00 ET
| Source:
Helsinn Healthcare S.A.
Helsinn Healthcare S.A.
20
21 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021.
Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that chan ....

United States , Paola Bonvicini , Riccardo Braglia , Mary Lynne Hedley , Purdue University , Helsinn Group Vice , Swiss Pharma Company , Abraxis Bioscience , Harvard University , Helsinn Group Media Contact , B Future Health Fund , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Helsinn Investment Fund , Eisai Inc , China Helsinn Pharmaceuticals , Ut Southwestern Medical Center , Group Head Of Communication , Centessa Pharmaceuticals , Business Development , Chief Operating Officer , Executive Vice President , Medical Affairs , Cellular Immunology , Medical Center , Youville Assisted Living Communities ,

Helsinn Healthcare S.A.: Helsinn appoints Mary Lynne Hedley to Board of Directors

Helsinn Healthcare S.A.: Helsinn appoints Mary Lynne Hedley to Board of Directors
20
21 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021.
Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that changed the treatment paradigm for women diagnosed with ovarian cancer. The company was acquired by GlaxoSm ....

United States , Paola Bonvicini , Riccardo Braglia , Mary Lynne Hedley , Purdue University , Helsinn Group Vice , Swiss Pharma Company , Abraxis Bioscience , Harvard University , Helsinn Group Media Contact , B Future Health Fund , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Helsinn Investment Fund , Eisai Inc , China Helsinn Pharmaceuticals , Ut Southwestern Medical Center , Group Head Of Communication , Centessa Pharmaceuticals , Business Development , Chief Operating Officer , Executive Vice President , Medical Affairs , Cellular Immunology , Medical Center , Youville Assisted Living Communities ,

Helsinn appoints Mary Lynne Hedley to Board of Directors

Helsinn appoints Mary Lynne Hedley to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Helsinn Grouphelsinn , Paola Bonvicini , Riccardo Braglia , Mary Lynne Hedley , Purdue University , Helsinn Group Vice , Swiss Pharma Company , Abraxis Bioscience , Harvard University , Helsinn Group Media Contact , B Future Health Fund , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Helsinn Investment Fund , Eisai Inc , China Helsinn Pharmaceuticals , Ut Southwestern Medical Center , Group Head Of Communication , Centessa Pharmaceuticals , Business Development , Wall Street , Chief Operating Officer , Executive Vice President , Medical Affairs , Cellular Immunology ,

Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan

Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South Korea , Paola Bonvicini , Sergio Cantoreggi , Riccardo Braglia , Helsinn Investment Fund , Helsinn Group Vice , Japanese Health Authorities , Swiss Pharma Company , China Helsinn Pharmaceuticals , Group Head Of Communication , Helsinn Group Media Contact , B Future Health Fund , Ono Pharmaceutical Co Ltd , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Cancer Cachexia , Japanese Minister , Helsinn Group Vice Chairman , Ono Pharmaceutical , Helsinn Group Chief Scientific Officer , Helsinn Healthcare , Helsinn Therapeutics , Helsinn Pharmaceuticals China , Helsinn Advanced Synthesis , Helsinn Birex Pharmaceuticals , Bfuture Health Fund ,

Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy .
Helsinn Healthcare S.A.February 18, 2021 GMT
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”).
Mechlorethamine gel 0.016%, also known as chlormethine gel, is approved for use in multiple countries including the US and EU and is marketed under the trade names VALCHLOR® and LEDAGA®. The authorized use for each country varies based on the design of the registrational trial and ....

Williaml Bailey , Larisaj Geskin , Paola Bonvicini , Helsinn Investment Fund , Helsinn Therapeutics Us Inc , Swiss Pharma Company , China Helsinn Pharmaceuticals , Group Head Of Communication , Helsinn Group Media Contact , Scientific Affairs , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Treatment Patterns , Mechlorethamine Gel , By Time Reanalysis , Randomized Controlled Phase , Clinical Lymphoma Myeloma , Systemic Absorption , Topical Mechlorethamine Gel , Mycosis Fungoides Cutaneoust Cell , Associate Professor , Columbia University Medical , Lead Author , By Time Reanalysis Manuscript , Systemic Absorption Research Letter , Helsinn Therapeutics ,